전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,019 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleHoffmann-La RochePhase 3

Tociluzumab (Tociluzumab)

Relapsed or Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase3#monoclonal-antibody#RelapsedorRefractoryFollicularLy+1
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 3

JS001 (Toripalimab, Toripalimab (JS001 ))

Urinary Bladder Neoplasms · Urinary Bladder Neoplasms

#UrinaryBladderNeoplasms#Antibody#Phase3#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab combine with Rituximab (Toripalimab combine with Rituximab)

Diffuse Large B-cell Lymphoma; Rituximab · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#Antibody#Phase2#monoclonal-antibody#Rituximab+1
Trials 1Status Active
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab, Rituximab (Toripalimab, Rituximab)

Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase2#monoclonal-antibody#High-gradeB-cellLymphoma+1
Trials 1Status Active
AntibodyLimited DatastaleGlaxoSmithKlinePhase 3

Tositumomab and Iodine I 131 Tositumomab (Tositumomab and Iodine I 131 Tositumomab)

Lymphoma, Non-Hodgkin · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase3#monoclonal-antibody#Lymphoma+2
Trials 1Status Active
AntibodyLimited DatastaleNorthwestern UniversityPhase 1

Transferrin Receptor-Targeted Liposomal p53 cDNA (Transferrin Receptor-Targeted Liposomal p53 cDNA)

Anatomic Stage IV Breast Cancer AJCC v8; Breast Inflammatory Carcinoma · Anatomic Stage IV Breast Cancer AJCC v8

#AnatomicStageIVBreastCancerAJCCv#Antibody#Phase1#monoclonal-antibody#BreastInflammatoryCarcinoma+1
Trials 1Status Discontinued
AntibodyLimited DatastaleChanghai HospitalPhase 2

TURBT (Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor, Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT))

Bladder Cancer · Bladder Cancer

#BladderCancer#Antibody#Phase2#monoclonal-antibody#Changhai
Trials 1Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 2

MEDI4736 (Tremelimumab Plus Durvalumab, Tremelimumab Plus Durvalumab (MEDI4736))

Hepatocellular Carcinoma (HCC); Unresectable Hepatocellular Carcinoma · Hepatocellular Carcinoma (HCC)

#HepatocellularCarcinomaHCC#Antibody#Phase2#monoclonal-antibody#UnresectableHepatocellularCarcin+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 2

Tremelimumab immunotherapy (Tremelimumab immunotherapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#AstraZeneca
Trials 1Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 2

Tremelimumab monotherapy (Tremelimumab monotherapy)

Urothelial Bladder Cancer; Triple-negative Breast Cancer · Urothelial Bladder Cancer

#UrothelialBladderCancer#Antibody#Phase2#monoclonal-antibody#Triple-negativeBreastCancer+1
Trials 1Status Active
AntibodyLimited DatastaleJanssenApproved

Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab (Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab)

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Approved#monoclonal-antibody#Janssen
Trials 1Status Active
AntibodyLimited DatastaleRocheApproved

Triamcinolone + Bevacizumab (Triamcinolone + Bevacizumab)

Diabetic Macular Edema · Diabetic Macular Edema

#DiabeticMacularEdema#Antibody#Approved#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 3

Triamcinolone Acetonide and Bevacizumab (Triamcinolone Acetonide and Bevacizumab)

Diffuse Diabetic Macular Edema · Diffuse Diabetic Macular Edema

#DiffuseDiabeticMacularEdema#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Discontinued
AntibodyLimited DatastaleQuantumLeap Healthcare Collabor…Phase 2

trastuzumab (Herceptin, Trilaciclib with or without trastuzumab + pertuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastNeoplasms+2
Trials 1Status Recruiting
CGTLimited DatastaleIntima Bioscience, Inc.Phase 2

TIL (Tumor-Infiltrating Lymphocytes, Tumor-Infiltrating Lymphocytes (TIL))

Gastrointestinal Epithelial Cancer; Gastrointestinal Neoplasms · Gastrointestinal Epithelial Cancer

#GastrointestinalEpithelialCancer#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 2

Tunlametinib + Cetuximab β (Tunlametinib + Cetuximab β)

Lung Cancer (NSCLC) · Lung Cancer (NSCLC)

#LungCancerNSCLC#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 2

UCART019 (UCART019)

B Cell Leukemia; B Cell Lymphoma · B Cell Leukemia

#BCellLeukemia#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleCellectis S.A.Phase 1

UCART123v1.2 (UCART123v1.2)

Relapsed/Refractory Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleInstitut de Recherches Internat…Phase 1

UCART19 (UCART19)

B-cell Acute Lymphoblastic Leukemia · B-cell Acute Lymphoblastic Leukemia

#B-cellAcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleCellectis S.A.Phase 1

UCARTCS1A (UCARTCS1A)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued

46 / 51 pages

← PreviousNext →